Pacira BioSciences, Inc.
http://www.pacira.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pacira BioSciences, Inc.
Finance Watch: VC Mega-Rounds Are Alive And Well
Private Company Edition: Also, Catalio closed a $381m venture capital fund and OrbiMed’s SEC filings indicate it is in the process of raising $4.75bn across three new funds. Dianthus launched with $100m and Tubulis closed a $63m series B round.
Axsome Is Latest To Falter With Technology For Unlocking Meloxicam’s Analgesic Potential
Axsome’s CRL was not the first from the US FDA for the nearly insoluble NSAID as sponsors try different technologies for delivering its pain relief quickly.
Pacira Aims For Non-Opioid Pipeline Growth With Flexion Buy
Flexion’s Zilretta is forecast to have big market potential with the growth of osteoarthritis, and Pacira’s CEO suggested there were commercial synergies with its Iovera device.
Heron Overcomes Two CRLs To Win Zynrelef Approval In Post-Op Pain
The combination of bupivacaine and meloxicam will be priced at a discount to Exparel, with Heron predicting rapid uptake. Label limited to three surgery types, but analysts expect off-label use.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Medical Devices
- Surgical Equipment & Devices
-
Biotechnology
- Liposomes
- Other Names / Subsidiaries
-
- Blue Acquisition Corp.
- DepoTech Corp.
- Flexion Therapeutics, Inc.
- myoscience, Inc.
- Pacira CryoTech, Inc.
- Pacira Pharmaceuticals, Inc.
- SkyePharma Inc.